Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in Pulmonary Tuberculosis
NCT00130247Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2002
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of isoniazid, rifampicin, pyrazinamide, ethambutol in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2002; status: completed.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00130247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130247.